NCT04868838View on ClinicalTrials.gov

Daratumumab to Treat Active Lupus Nephritis

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Lupus Nephritis

Interventions

DRUG

Daratumumab

1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester